|
Name |
(4R,5R,6E,8S,9R)-5-[(E)-2-Methyl-2-butenoyloxy]-4,8,9-trihydroxy-6-decenoic acid 1,4-lactone
|
| Molecular Formula | C15H22O6 | |
| IUPAC Name* |
[(E,1R,4S,5R)-4,5-dihydroxy-1-[(2R)-5-oxooxolan-2-yl]hex-2-enyl] (E)-2-methylbut-2-enoate
|
|
| SMILES |
C/C=C(\C)/C(=O)O[C@H](/C=C/[C@@H]([C@@H](C)O)O)[C@H]1CCC(=O)O1
|
|
| InChI |
InChI=1S/C15H22O6/c1-4-9(2)15(19)21-13(6-5-11(17)10(3)16)12-7-8-14(18)20-12/h4-6,10-13,16-17H,7-8H2,1-3H3/b6-5+,9-4+/t10-,11+,12-,13-/m1/s1
|
|
| InChIKey |
KDJQJYVWRNNMAM-SUOUKJKBSA-N
|
|
| Synonyms |
(1R,2E,4S,5R)-1-[(2R)-5-oxotetrahydrofuran-2-yl]-4,5-dihydroxy-hex-2-en-1-yl(2E)-2-methylbut-2-enoate; (4R,5R,6E,8S,9R)-5-[(E)-2-Methyl-2-butenoyloxy]-4,8,9-trihydroxy-6-decenoic acid 1,4-lactone
|
|
| CAS | NA | |
| PubChem CID | 122372757 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 298.33 | ALogp: | 0.8 |
| HBD: | 2 | HBA: | 6 |
| Rotatable Bonds: | 7 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 93.1 | Aromatic Rings: | 1 |
| Heavy Atoms: | 21 | QED Weighted: | 0.436 |
| Caco-2 Permeability: | -4.905 | MDCK Permeability: | 0.00007770 |
| Pgp-inhibitor: | 0.006 | Pgp-substrate: | 0.015 |
| Human Intestinal Absorption (HIA): | 0.968 | 20% Bioavailability (F20%): | 0.026 |
| 30% Bioavailability (F30%): | 0.986 |
| Blood-Brain-Barrier Penetration (BBB): | 0.707 | Plasma Protein Binding (PPB): | 75.94% |
| Volume Distribution (VD): | 0.764 | Fu: | 11.41% |
| CYP1A2-inhibitor: | 0.11 | CYP1A2-substrate: | 0.151 |
| CYP2C19-inhibitor: | 0.117 | CYP2C19-substrate: | 0.401 |
| CYP2C9-inhibitor: | 0.067 | CYP2C9-substrate: | 0.836 |
| CYP2D6-inhibitor: | 0.026 | CYP2D6-substrate: | 0.127 |
| CYP3A4-inhibitor: | 0.18 | CYP3A4-substrate: | 0.223 |
| Clearance (CL): | 2.162 | Half-life (T1/2): | 0.879 |
| hERG Blockers: | 0.018 | Human Hepatotoxicity (H-HT): | 0.681 |
| Drug-inuced Liver Injury (DILI): | 0.511 | AMES Toxicity: | 0.015 |
| Rat Oral Acute Toxicity: | 0.358 | Maximum Recommended Daily Dose: | 0.836 |
| Skin Sensitization: | 0.156 | Carcinogencity: | 0.047 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.015 |
| Respiratory Toxicity: | 0.057 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003192 | ![]() |
1.000 | D0E9KA | ![]() |
0.200 | ||
| ENC003191 | ![]() |
0.647 | D0ZI4H | ![]() |
0.195 | ||
| ENC001863 | ![]() |
0.474 | D0S8LV | ![]() |
0.192 | ||
| ENC005693 | ![]() |
0.341 | D02IIW | ![]() |
0.187 | ||
| ENC001864 | ![]() |
0.333 | D05ZTH | ![]() |
0.185 | ||
| ENC005821 | ![]() |
0.301 | D0N3NO | ![]() |
0.182 | ||
| ENC005692 | ![]() |
0.300 | D0T8LY | ![]() |
0.173 | ||
| ENC005531 | ![]() |
0.280 | D00NPP | ![]() |
0.172 | ||
| ENC000899 | ![]() |
0.278 | D0Q4TK | ![]() |
0.171 | ||
| ENC005196 | ![]() |
0.278 | D02RQU | ![]() |
0.171 | ||